Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Effectiveness in treating weakness associated with Lambert-Eaton Myasthenic Syndrome(LEMS) based on the Medical Research Council (MRC) 12 point quantitative scale.
Treatment period for each subject depends on the availability of 3,4 -DAP through the Expanded Access program from Jacobus Pharmaceutical Company,Inc.
Steven P Ringel, MD
University of Colorado, Denver
United States: Food and Drug Administration
|University of Colorado||Denver, Colorado 80217|